Lymphocytes in Peritumoral Stroma: Evaluation in Epithelial Ovarian Neoplasms

References

• American Cancer Society. (2019). Cancer facts & figures 2019. Special section: ovarian cancer. Atlanta, GA. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf. Accessed February 14, 2019.
   Google Scholar
• Bremnes RM, Dønnem T, Al-Saad S, et al. (2011). The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol, 6, 209–217.
   PubMed Web of Science ®Google Scholar
• Bronte V, Cingarlini S, Marigo I, et al. (2006). Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol Invest, 35(3–4), 327–357.
   PubMed Web of Science ®Google Scholar
• Clarke B, Tinker AV, Lee CH, et al. (2009). Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol, 22, 393–402.
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR. (2010). Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle, 9, 260–268.
   PubMed Web of Science ®Google Scholar
• Globocan. (2019). International Agency for Research on Cancer (IARC)/Cancer Registries International Agency for Research on Cancer, Worl Health Organization. Lyon, France. http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed March 20, 2019.
   Google Scholar
• Hamanishi J, Mandai M, Abiko K, et al. (2011). The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol, 141, 338–347.
   PubMed Web of Science ®Google Scholar
• Jammal MP, Martins-Filho A, Silveira TP, et al. (2014). Cytokines and prognostic factors in epithelial ovarian cancer. Clin Med Insights Oncol, 2, 71–76.
   Google Scholar
• Jia L, Ren JM, Wang YY. (2014). Inhibitory role of prohibiting in human ovarian epithelial cancer. Int J Clin Exp Pathol, 7, 2247–2255.
   PubMed Web of Science ®Google Scholar
• Kroeger DR, Milne K, Nelson BH. (2016). Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, Cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res, 22, 3005–3015.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih I. (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol, 34, 433–443.
   PubMed Web of Science ®Google Scholar
• Le Page C, Marineau A, Bonza PK, et al. (2012). BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS One, 7, e38541.
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Chen R, et al. (2017). The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget, 8, 15621–15631.
   PubMedGoogle Scholar
• Lukesova S, Vroblova V, Tosner J, et al. (2015). Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. Contemp Oncol (Pozn), 19, 290–299.
   PubMed Web of Science ®Google Scholar
• Martins-Filho A, Jammal MP, Micheli DC, et al. (2017). Role of intracystic cytokines and Nitric Oxide in ovarian neoplasms. Scand J Immunol, 86(6), 462–470.
   PubMed Web of Science ®Google Scholar
• Montfort A, Pearce O, Maniati E, et al. (2017). A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin Cancer Res, 23, 250–262.
   PubMed Web of Science ®Google Scholar
• Murta EF, Nomelini RS. (2006). Early diagnosis and predictors of malignancy of adnexal masses. Curr Opin Obstet Gynecol, 18, 14–19.
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Sahota RA, Milne K, et al. (2012). CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res, 18, 3281–3292.
   PubMed Web of Science ®Google Scholar
• Pinto MP, Balmaceda C, Bravo ML, et al. (2018). Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. Gynecol Oncol, 151, 10–17.
   PubMed Web of Science ®Google Scholar
• Rådestad E, Klynning C, Stikvoort A, et al. (2018). Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. Oncoimmunology, 8, e1535730.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Pinto D. (2005). B cells as antigen presenting cells. Cell Immunol, 238, 67–75.
   PubMed Web of Science ®Google Scholar
• Sanguinete MMM, Oliveira PH, Martins-Filho A, et al. (2017). Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol Invest, 46(7), 677–688.
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A, 102, 18538–18543.
   PubMed Web of Science ®Google Scholar
• Singh M, Loftus T, Webb E, Benencia F. (2016). Minireview: regulatory T cells and ovarian cancer. Immunol Invest, 45(8), 712–720.
   PubMed Web of Science ®Google Scholar
• Stone B, Schummer M, Paley PJ, et al. (2003). Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer, 104, 73–84.
   PubMed Web of Science ®Google Scholar
• Valmori D, Ayyoub M. (2014). CD4(+) T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs. Oncoimmunology, 4, e946370.
   PubMed Web of Science ®Google Scholar
• Wang Q, Lou W, Di W, Wu X. (2017). Prognostic value of tumor PD-L1 expression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer. Int Immunopharmacol, 52, 7–14.
   PubMed Web of Science ®Google Scholar
• Yang L, Wang S, Zhang Q, et al. (2018). Clinical significance of the immune microenvironment in ovarian cancer patients. Mol Omics, 14, 341–351.
   PubMed Web of Science ®Google Scholar
• Yildirim N, Akman L, Acar K, et al. (2017). Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?. Eur J Obstet Gynecol Reprod Biol, 215, 55–61.
   PubMed Web of Science ®Google Scholar
• Zeppernick F, Meinhold-Heerlein I. (2014). The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet, 290, 839–842.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med, 348, 203–213.
   PubMed Web of Science ®Google Scholar
• Zhang S, Ke X, Zeng S, et al. (2015). Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment. Cell Mol Immunol, 12, 580–591.
   PubMed Web of Science ®Google Scholar